Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

1.320 -0.180 (-12.01%)
Streaming Delayed Price Updated: 3:53 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nexalin Technology, Inc. - Common Stock

< Previous 1 2 3 Next >
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™ 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated... 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and... 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2 
From Nexalin Technology, Inc.
Via GlobeNewswire
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment 
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
From Nexalin Technology, Inc.
Via GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
From Nexalin Technology, Inc.
Via GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
From Nexalin Technology, Inc.
Via GlobeNewswire
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESSWIRE
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.